Search results
Showing 91 to 105 of 595 results for women's health
This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
Prucalopride for the treatment of chronic constipation in women (TA211)
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.
This guideline covers how local communities, with support from local organisations and networks, can help prevent people from becoming overweight or obese or help them lose weight. It aims to support sustainable and community-wide action to achieve this.
Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
This quality standard covers preventing bacterial infection in newborn babies, treating pregnant women and pregnant people whose babies are at risk of infection, and treating newborn babies with suspected or confirmed bacterial infection. It includes when to give antibiotics to prevent and treat neonatal bacterial infection and describes high-quality care in priority areas for improvement. This includes early-onset (within 72 hours of birth) and late-onset (between 72 hours and 28 days following birth) neonatal infection.
View quality statements for QS75Show all sections
Sections for QS75
- Quality statements
- Quality statement 1: Intrapartum antibiotics
- Quality statement 2: Assessment for early-onset neonatal infection
- Quality statement 3: Prompt antibiotic treatment for neonatal infection
- Quality statement 4: Reassessing antibiotic treatment for neonatal infection
- Quality statement 5: Information and support for parents and carers
- Update information
- About this quality standard
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype
newborns Women can develop mental ill health for the first time during pregnancy, and pre-existing mental...
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
This guideline covers recognising, assessing and treating bipolar disorder (formerly known as manic depression) in children, young people and adults. The recommendations apply to bipolar I, bipolar II, mixed affective and rapid cycling disorders. It aims to improve access to treatment and quality of life in people with bipolar disorder.
Healthy start vitamins: special report on cost effectiveness (ECD5)
Healthy start vitamins: special report on cost effectiveness